India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Can exercise reduce the effects of cancer? A study in the New England Journal of Medicine has shown that exercise reduces the risk of cancer recurrence and death. The study showed that a 6-month exercise program has a positive effect on the physical health of cancer patients. Experts have suggested that exercise should be made an essential part of cancer treatment and included in daily lifestyle. We all know that physical exercise has many benefits. Exercise has the power to control chronic diseases such as diabetes, high blood pressure and heart disease. Experts say that not only these diseases, but also cancer can be beneficial if you exercise daily. According to a new study conducted by the New England Journal of Medicine, cancer patients who engage in a systematic exercise program are less likely to have cancer recurrence. They have been able to live longer than other cancer patients. How did exercise improve cancer? What is the main information this study is trying to provid...